Sheet 1 of 2 FORM PTO-1445 TRAPE U.S. DEPARTMENT OF COMMERCE ATTY DOCKET NO : SERIAL NO.: 10/056,348 PATENT AND TRADEMARK OFFICE 200.1079CON4 (REV. 7-80) APPLICANT(S): Ronald M. BURCH, et al. LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) FILING DATE: GROUP: 1639 January 25, 2002 U.S. PATENT DOCUMENTS CLASS SUBCLASS *EXAMINER DOCUMENT NUMBER DATE NAME FILING DATE IF APPROPRIATE INITIAL AΑ AB POREIGN PATENT DOCUMENTS CLASS SUBCLASS TRANSLATION DOCUMENT NUMBER COUNTRY YES NO AD OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Degner, Frank, et al., "Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patients with AG Rheumatic Disease*, Clin Therapeutics (Nov 2000) 22: 400-410. Lanes, Stephan et al., "Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, /S.L./ ΔН Diclofenac, Naaproxen and Indomethacin", Pharmacoepidemiology and Drug Safety (2000) 9:113-117. Translation of Office Action dated November 1, 2001, issued in connection with Russian Federation Patent Application No. 2000109552 STN: File Registry printout of Registry Number 162054-19-5 (June 14, 2004). Abstract of SANTOS et al., *Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in Mice." Inflammation Research (1998), 47(7) pages 302-307, Chem. Abst. Vol. 129 (Columbus, OH) FRÖLICH, J.C., "A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes," TiPS, AL January 1997, vol. 18, pages 30-34. Abstract of OGINO K, et al., "Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1," Pharmacology 55(1):44-53, July 1997 Abstract of ISAKSON P. et al., "Discovery of a better aspirin," Advances in Prostaglandin, Thromboxane, & Leukofriene Research 23:49-54, 1995 ΑN

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

a consensus statement using a meta-analytic approach", Ann Rhuem Dis (2004) 64:759-766.

anti-inflammatory drus," Drugs 53(4):563-82, April 1997.

Rheumatology, Supplement 47:40-7, February 1997.

ΑO

ΔP

EXAMINER

Abstract of JOUZEAU J.Y. et al., "Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal

Richy, F., et al., "Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use:

DATE CONSIDERED 05/27/2008

Abstract of DVORNIK D.M., "Tissue selective inhibition of prostaglandin biosynthesis by etodolac," Journal of

| | \ | , MOI | - | | થ | | | | | | | | | | | | |
|--|--------|--------------|--|---|--------|---------|-------|--|--|------------------------------|---|---------------|----------------------|-------------------------------|----|--|--|
| FORM PTO-144 TRADEMIC U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMIC PATENT AND TRADEMARK OFFICE | | | | | | | | | | ATTY. DOCKET 200.1079CON4 | NO.: | SERIAL NO.: 1 | RIAL NO.: 10/056,348 | | | | |
| LIST OF PRIOR ART CITED BY APPLICANT | | | | | | | | | APPLICANT(S): Ronald M. BURCH, et al. | | | | | | | | |
| (Use several sheets if necessary) | | | | | | | | | FILING DATE: GROUP: 1639 January 25, 2002 | | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | | DOCUMENT NUMBER DATE | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | |
| | | BA | | | | | | | | | | | | | | | |
| | | ВВ | _ | _ | | | | | | | | | | | | | |
| | | вс | | | - | 1 | 1 | | | | | | | | | | |
| FOREIGN MAIENT BUCUMENTS | | | | | | | | | | | | | | | | | |
| | | | DOCUMENT NUMBER DATE | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | | | |
| | | | | | | | | | | | | | | YES | NO | | |
| | | BD | | - | | | П | | Γ | | | i | - | | | | |
| | | - | | | | | _ | | | | | 1 | | - | - | | |
| BE OTHER PROPERTY AND A STATE OF THE PARTY O | | | | | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) /S.L./ BF Goodman & Gillman's (1999). The Pharmacological Basis of Therapeutics, 9 th Edition, McGraw-Hill, New York, pp. 654-61 | | | | | | | | | | | | | | 654 655 | | | |
| /S.L./ | | Br | | | | | | | | | | | | | | | |
| /O.L./ | | BG | Abstract of FLOWER R. J., "New directions in cyclooxygenase research and their implications for NSAID-gastropathy," Italian Journal of Gastroenterology, 28 Suppl. 4:23-7, December 1996. | | | | | | | | | | | | | | |
| | | вн | Abstract of KURUMBAIL R.G. et al., "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents," Nature, 384(6510):644-8, December 19-26, 1996. | | | | | | | | | | | | | | |
| | | ВІ | | Abstract of HOSIE J. et al., "Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium," British Journal of Rheumatology, 35 Suppl. 1:39-43, April 1996. | | | | | | | | | | | | | |
| | | ВЈ | | Abstract of PAIRET M. et al., "Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications," Fundamental & Clinical Pharmacology 10(1):1-17, 1996. | | | | | | | | | | | | | |
| | | ВК | Abstract of MASFERRER J.L. et al, "Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract," Castroenterology Clinics of North America 25(2):363-72, June 1996. | | | | | | | | | | | | | | |
| | | BL | Abstract of EMERY P., "Clinical implications of selective cycloxygenase-2 inhibiton," Scandinavian Journal of Rheumatology-Supplement 102:23-8, 1996. | | | | | | | | | | | | | | |
| | | вм | Van Hecken, Anne, et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers". J Clin Pharmacol (2000) 40: 1109-1120. | | | | | | | | | | | | | | |
| | | | | | | | | | | | , | | | | | | |
| | , | BN | | | | | | | | | | | | | | | |
| V | | во | | | | | | | | | | | | | | | |
| EXAM | INER | /Sue Liu/ | | | | | | | | | DATE CONSIDERED 05/27/2008 | | | | | | |
| *EY^* | AINEC: | Initial if - | oforor - | | noide: | rad vid | hothe | | d oitet | ion is in co-f- | rmance with MPEP | 600: Draw ! | ing through citatia | on if not in | | | |
| | | | | | | | | | | | | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.